China Grand Pharmaceutical announced the successful set up of AuroRNA Biotech, a joint venture between eTheRNA immunotherapies and China Grand Pharmaceutical.
AuroRNA will use eTheRNA’s mRNA manufacturing platform and proprietary lipid nanoparticle delivery technology to produce and commercialize mRNA products in Greater China, and selected other regions. AuroRNA will also license in other products from eTheRNA, while also co-developing new products with the assistance of eTheRNA. As a first product, AuroRNA has in-licensed eTheRNA’s flagship HPV-positive head & neck cancer vaccine.
Earlier this year, Agio Capital & Business Solutions supported the equity investment from China Grand Pharmaceutical into eTheRNA with the outline of a strategic partnership.
Want to find out more? Click here to read the article.